Bintrafusp alfa

Unassigned

New Medicines

Bile duct cancer (cholangiocarcinoma) - second-line

Information

New molecular entity
GlaxoSmithKline
GlaxoSmithKline

Development and Regulatory status

Phase II Clinical Trials
Phase II Clinical Trials
Phase II Clinical Trials
Yes

Category

A bifunctional fusion antibody that simultaneously targets the transforming growth factor-β (TGF-β) trap and an anti-programmed cell death ligand-1 (PD-L1)
Cholangiocarcinoma arises from the cells within the bile ducts. It is often diagnosed late (stages III and IV) and the prognosis is poor. It is most common in those over 70 years old and is more common in men than women [1]. Incidence is 1-2 per 100,000 population per year in the UK [2].
Bile duct cancer (cholangiocarcinoma) - second-line
Intravenous infusion